Alnylam Pharmaceuticals IncNASDAQ:ALNY
- LAST PRICE279.1500
- TODAY'S CHANGE (%)6.0000 (2.1966%)
- Bid / Lots278.8500/ 3
- Ask / Lots279.4600/ 2
- Open / Previous Close276.5300 / 273.1500
- Day Range
- 52 Week Range
- Volume173,494
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ALNY |
|---|---|---|
| 09:32 ET | 8407 | 277.24 |
| 09:34 ET | 100 | 276.22 |
| 09:36 ET | 200 | 277.46 |
| 09:41 ET | 732 | 276.39 |
| 09:43 ET | 100 | 276.44 |
| 09:45 ET | 881 | 277.37 |
| 09:48 ET | 300 | 277.41 |
| 09:50 ET | 603 | 277.575 |
| 09:52 ET | 1600 | 276.46 |
| 09:54 ET | 1600 | 276.22 |
| 09:56 ET | 550 | 276.33 |
| 09:57 ET | 864 | 276.76 |
| 10:01 ET | 800 | 276.74 |
| 10:06 ET | 725 | 276.42 |
| 10:08 ET | 1100 | 277.12 |
| 10:10 ET | 700 | 277.63 |
| 10:12 ET | 200 | 277.49 |
| 10:14 ET | 1285 | 278.165 |
| 10:15 ET | 100 | 278.47 |
| 10:17 ET | 2800 | 278.33 |
| 10:19 ET | 400 | 278.605 |
| 10:21 ET | 3078 | 277.98 |
| 10:24 ET | 900 | 278.24 |
| 10:26 ET | 2623 | 277.7 |
| 10:28 ET | 300 | 277.3725 |
| 10:30 ET | 100 | 277.37 |
| 10:33 ET | 2212 | 277.38 |
| 10:35 ET | 4131 | 278.2 |
| 10:37 ET | 1100 | 278.22 |
| 10:39 ET | 199 | 278.2 |
| 10:42 ET | 200 | 278.565 |
| 10:44 ET | 843 | 278.635 |
| 10:46 ET | 300 | 278.635 |
| 10:48 ET | 2150 | 278.25 |
| 10:50 ET | 300 | 277.66 |
| 10:53 ET | 200 | 277.815 |
| 10:55 ET | 1000 | 277.52 |
| 10:57 ET | 400 | 277.085 |
| 11:00 ET | 600 | 277.025 |
| 11:02 ET | 3822 | 277.0825 |
| 11:04 ET | 600 | 277.04 |
| 11:06 ET | 1493 | 277.35 |
| 11:08 ET | 4683 | 277.38 |
| 11:09 ET | 100 | 277.225 |
| 11:13 ET | 1113 | 277.67 |
| 11:15 ET | 3276 | 277.89 |
| 11:18 ET | 600 | 277.695 |
| 11:22 ET | 3305 | 279.26 |
| 11:24 ET | 1000 | 279.09 |
| 11:26 ET | 305 | 279.09 |
| 11:27 ET | 1400 | 279.1 |
| 11:29 ET | 2853 | 278.59 |
| 11:31 ET | 200 | 278.8 |
| 11:33 ET | 3382 | 278.64 |
| 11:36 ET | 300 | 278.54 |
| 11:38 ET | 1000 | 278.985 |
| 11:42 ET | 1200 | 279.081 |
| 11:44 ET | 1896 | 279.4 |
| 11:45 ET | 1960 | 278.86 |
| 11:47 ET | 100 | 278.66 |
| 11:49 ET | 859 | 278.87 |
| 11:51 ET | 800 | 278.67 |
| 11:54 ET | 500 | 278.75 |
| 11:56 ET | 300 | 278.815 |
| 11:58 ET | 1300 | 279.08 |
| 12:00 ET | 3275 | 278.71 |
| 12:02 ET | 2583 | 278.6075 |
| 12:03 ET | 5300 | 278.94 |
| 12:05 ET | 1200 | 278.81 |
| 12:07 ET | 5277 | 279.02 |
| 12:09 ET | 3418 | 279.15 |
| 12:12 ET | 300 | 278.96 |
| 12:16 ET | 478 | 279.15 |
Today
Sep 12, 2024
DJ The Brawl Taking Shape Over Pfizer's Multibillion-Dollar Heart Monopoly -- Heard on the Street -- Update, from 1:01PM ET on Thursday Sep 12, 2024 by Dow Jones
1:01PM ET on Thursday Sep 12, 2024 by Dow JonesDJ The Brawl Taking Shape Over Pfizer's Multibillion-Dollar Heart Monopoly -- Heard on the Street -- WSJ, from 7:00AM ET on Thursday Sep 12, 2024 by Dow Jones
7:00AM ET on Thursday Sep 12, 2024 by Dow Jones
Sep 9, 2024
DJ Alnylam Pharmaceuticals Price Target Maintained With a $220.00/Share by Cantor Fitzgerald, from 11:21AM ET on Monday Sep 09, 2024 by Dow Jones
11:21AM ET on Monday Sep 09, 2024 by Dow Jones
Sep 4, 2024
DJ Alnylam Pharmaceuticals Price Target Maintained With a $300.00/Share by RBC Capital, from 9:41AM ET on Wednesday Sep 04, 2024 by Dow Jones
9:41AM ET on Wednesday Sep 04, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Alnylam Pharmaceuticals Inc | 35.1B | -444.2x | --- |
argenx SE | 31.6B | -153.8x | --- |
Beigene Ltd | 21.9B | -39.6x | --- |
United Therapeutics Corp | 15.2B | 16.1x | +8.22% |
Neurocrine Biosciences Inc | 12.1B | 37.0x | +62.04% |
Medpace Holdings Inc | 11.2B | 35.1x | +35.10% |
Company Information
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. In addition, the Company develops Cemdisiran to treat complement-mediated diseases, Belcesiran for the treatment of alpha-1 liver disease, Elebsiran, Zilebesiran, ALN-APP, ALN-HSD, Fitusiran, and others.
Contact Information
- Headquarters
- 675 W Kendall StCAMBRIDGE, MA, United States 02142-1168
- Phone
- 617-551-8200
- Fax
- 617-551-8101
Executives
- Independent Chairman of the Board
- Amy Schulman
- Chief Executive Officer, Director
- Yvonne Greenstreet
- Chief Financial Officer, Executive Vice President
- Jeffrey Poulton
- Executive Vice President, Chief Scientific Officer, Head - Early Research and Early Development
- Kevin Fitzgerald
- Chief Medical Officer, Executive Vice President - Development and Medical Affairs
- Pushkal Garg
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $35.1B |
|---|---|
Revenue (TTM) | $2.3B |
Shares Outstanding | 128.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.38 |
EPS | $-0.63 |
Book Value | $-1.75 |
P/E Ratio | -444.2x |
Price/Sales (TTM) | 15.0 |
Price/Cash Flow (TTM) | --- |
Operating Margin | 4.38% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
